VENTYX BIOSCIENCES, INC. INVESTOR ALERT (NASDAQ: VTYX): The

NEW YORK, May 11, 2024 (GLOBE NEWSWIRE) — If you are a shareholder of Ventyx Biosciences, you can obtain further information by contacting Ross Shikowitz at [email protected], calling us at 212-789-3619 or by visiting https Visit ://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.

There are no costs for you.

Why is Ventyx being investigated by the BFA?

Directors and officers of a company have fiduciary duties to the company and its shareholders. Bleichmar Fonti & Auld is investigating whether Ventyx’s directors breached these fiduciary duties and/or engaged in other securities law violations.

What can you do?

If you are a shareholder of Ventyx Biosciences, Inc., you may have legal options. All representations are made on a contingency fee basis. The shareholders are not responsible for any court costs or litigation costs. The Company will seek court approval for any fees and expenses.

For further information please contact:

Ross Shikowitz
[email protected]
212-789-3619
https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder derivative litigation. It was named one of the top five plaintiff law firms by ISS SCAS in 2023 and its attorneys were named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Recent notable successes include BFA being valued at over $900 million by the board of Tesla, Inc. (pending court approval) and $420 million by Teva Pharmaceutical Ind. Ltd. has requested back.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

Lawyer advertising. Past results are no guarantee of future results.